Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Creative Medical Technology Holdings ( (CELZ) ) just unveiled an update.
At its 2025 Annual Meeting of Stockholders held on December 18, 2025, Creative Medical Technology Holdings, Inc. reported that shareholders representing 61.5% of outstanding common stock were present in person or by proxy, establishing a quorum. All five director nominees—Timothy Warbington, Donald Dickerson, Michael H. Finger, Susan Snow, and Bruce S. Urdang—were elected to the board, the compensation of the company’s named executive officers was approved, and shareholders ratified the appointment of Haynie & Company as the company’s independent registered public accounting firm. The voting outcomes reaffirmed the company’s current leadership, executive pay practices, and audit oversight structure, providing continuity in governance and financial reporting for investors and other stakeholders.
The most recent analyst rating on (CELZ) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Creative Medical Technology Holdings stock, see the CELZ Stock Forecast page.
More about Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. operates in the medical and healthcare sector, focusing on developing and commercializing innovative therapeutic technologies. The company’s governance and executive leadership structure are overseen by a board of directors and named executive officers whose compensation and oversight are subject to shareholder approval at its annual meetings.
Average Trading Volume: 101,345
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.46M
For detailed information about CELZ stock, go to TipRanks’ Stock Analysis page.